Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
ASTELLAS PHARMA
🇯🇵
Japan
Country
🇯🇵
Japan
Ownership
-
Established
2005-01-01
Employees
-
Market Cap
$22.5B
Website
https://www.astellas.com/
Clinical Trials
Related News
Protopic Ointment in Adult Atopic Eczema of the Face
Phase 4
Completed
Conditions
Dermatitis, Atopic
Interventions
Drug: tacrolimus 0.1%
Drug: fluticasone 0.005 %
Subscribe
First Posted Date
2008-06-04
Last Posted Date
2014-09-01
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
577
Registration Number
NCT00690105
Subscribe
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Phase 3
Completed
Conditions
Urinary Bladder, Overactive
Interventions
Drug: Mirabegron
Drug: Tolterodine
Drug: Placebo to Mirabegron
Drug: Placebo to Tolterodine
Subscribe
First Posted Date
2008-06-03
Last Posted Date
2024-11-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
2792
Registration Number
NCT00688688
Subscribe
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Phase 3
Completed
Conditions
Urinary Bladder, Overactive
Interventions
Drug: Mirabegron
Drug: Tolterodine
Drug: Placebo to Mirabegron
Drug: Placebo to Tolterodine
Subscribe
First Posted Date
2008-06-03
Last Posted Date
2024-11-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
2336
Registration Number
NCT00689104
Subscribe
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
Conditions
Chronic Plaque Psoriasis
Interventions
Drug: alefacept
Subscribe
First Posted Date
2008-05-07
Last Posted Date
2014-08-26
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
78
Registration Number
NCT00674063
Subscribe
A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
Phase 3
Completed
Conditions
Chronic Plaque Psoriasis
Interventions
Drug: placebo
Drug: alefacept
Subscribe
First Posted Date
2008-05-07
Last Posted Date
2014-08-26
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
195
Registration Number
NCT00673556
Subscribe
A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831
Phase 2
Completed
Conditions
Non-Alcoholic Steatohepatitis
Interventions
Drug: ASP9831
Drug: Placebo
Subscribe
First Posted Date
2008-04-28
Last Posted Date
2013-03-21
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
114
Registration Number
NCT00668070
Subscribe
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis
Phase 4
Completed
Conditions
Dermatitis, Atopic
Interventions
Drug: tacrolimus ointment
Drug: pimecrolimus cream
Subscribe
First Posted Date
2008-04-25
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
426
Registration Number
NCT00667160
Subscribe
Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis
Phase 4
Completed
Conditions
Dermatitis
Interventions
Drug: tacrolimus ointment
Drug: placebo ointment
Subscribe
First Posted Date
2008-04-25
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
98
Registration Number
NCT00667056
Subscribe
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis
Phase 4
Completed
Conditions
Dermatitis, Atopic
Interventions
Drug: tacrolimus ointment
Drug: pimecrolimus cream
Subscribe
First Posted Date
2008-04-24
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
226
Registration Number
NCT00666159
Subscribe
Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis
Phase 3
Completed
Conditions
Candidiasis, Oral
Interventions
Drug: Fluconazole
Drug: Micafungin
Subscribe
First Posted Date
2008-04-24
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
523
Registration Number
NCT00666185
Locations
🇿🇦
2 Sites, Port Elizabeth, South Africa
🇵🇪
4 Sites, Lima, Peru
🇧🇷
8 Sites, Sao Paulo, Brazil
and more 2 locations
Subscribe
Prev
1
34
35
36
37
38
52
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy